LumaCina today announced that it has secured a permanent national supply solution for morphine oral liquid, restoring reliable access for hospitals, pharmacies, and palliative care services across Australia.
Following the withdrawal of Ordine, clinicians and patients faced constrained options for immediate-release morphine oral liquid. LumaCina has leveraged its global network to establish long-term supply arrangements and to make multiple strengths and pack sizes available so that providers can continue to deliver essential pain relief where it is needed most.
“Access to morphine is not optional. It is a matter of dignity and care for patients at the most vulnerable stages of life,” said Anthony Boteju, Vice President of Sales and Marketing at LumaCina. “Working closely with regulators, prescribers, and pharmacists, we have moved from stop-gap measures to a permanent, dependable solution.”
LumaCina’s products closely mirror the formulations and presentations previously in use, helping clinicians and caregivers manage any transition safely. The company is collaborating with health authorities and professional bodies on guidance and education to support accurate dosing and consistent practice.
With a permanent solution now established, LumaCina will continue to monitor demand, maintain appropriate inventory across the supply chain, and support providers to ensure uninterrupted patient care.
